It's Not Trivial: Tryvio, a New Treatment for Resistant Hypertension
by Jaiden M. Riemer, 2025 PharmD Candidate
Abstract:
Aprocitentan was approved by the Food and Drug Administration (FDA) in March of 2024 after publication of the phase three PRECISION trial for the use of treatment-resistant hypertension. Aprocitentan antagonizes endothelin A and B, a receptor not currently targeted by any guideline- recommended antihypertensive agent. Its mechanism of action prevents endothelin 1 from binding to endothelin A and B receptor sites. The trial studied doses of aprocitentan at 12.5 mg and 25 mg, revealing common adverse effects of edema and anemia and concerns for use in patients with poor renal function or in pregnancy. Despite the FDA’s approval of aprocitentan in March 2024, it has yet to be determined where it fits in therapy.
Keywords: Hypertension, aprocitentan, Cardiovascular Disease, Antihypertensive Agents, Endothelin-1
Download PDF
2025 March/April Table of Contents
Abstract:
Aprocitentan was approved by the Food and Drug Administration (FDA) in March of 2024 after publication of the phase three PRECISION trial for the use of treatment-resistant hypertension. Aprocitentan antagonizes endothelin A and B, a receptor not currently targeted by any guideline- recommended antihypertensive agent. Its mechanism of action prevents endothelin 1 from binding to endothelin A and B receptor sites. The trial studied doses of aprocitentan at 12.5 mg and 25 mg, revealing common adverse effects of edema and anemia and concerns for use in patients with poor renal function or in pregnancy. Despite the FDA’s approval of aprocitentan in March 2024, it has yet to be determined where it fits in therapy.
Keywords: Hypertension, aprocitentan, Cardiovascular Disease, Antihypertensive Agents, Endothelin-1
Download PDF
2025 March/April Table of Contents